

Shaping the Future of Evidence Generation: Real-world Data to Drive Healthcare Transformation and Patient-centered Decisions

Jesús Medina¹, Joaquín Sánchez-Covisa¹, Javier Nuevo¹, Marta Galvez-Fernández¹, Alberto García¹, Belén Pimentel¹, Eunice Fitas¹, Eduardo Fernández², Ryan N. Walton³, Meri Petrovska⁴ and Ana Pérez Domínguez^{1,*}

¹AstraZeneca Spain, Medical Affairs department, Madrid, Spain

²AstraZeneca Spain, Innovation and Digital Strategy department, Madrid, Spain.

³AstraZeneca, Biopharmaceuticals Medical, Real World Science and Analytics, Mississauga, Canada

⁴AstraZeneca, Biopharmaceuticals Medical, Real World Science and Analytics, Cambridge, United Kingdom

***Corresponding author**

Ana Pérez Domínguez

AstraZeneca Farmacéutica Spain

C. del Puerto de Somport 21-23, Fuencarral-El Pardo, 28050 Madrid

Ana.Perez.Dominguez@astrazeneca.com

Table S1. Summary of studies/initiatives mentioned in the manuscript and intended downstream application.

Component classification	Type of evidence	Study or initiative name (or lead author)	Disease/condition	Strategic purpose or downstream application*	Intended audience	References
Enhanced therapeutic area knowledge	RWE generation about diseases and their management	PATHWAYS-HF	HF	A	Payers, HCSAs, HCPs	[1]
		EXACOS-CV	COPD	F, H	Payers, HCSAs, HCPs	[2, 3]
		Alcázar-Navarrete et al.	COPD	B, F	Payers, HCSAs, HCPs	[4]
		CaReMe	CKD	B, H	Payers, HCSAs, HCPs	[5]
		ENDO-CKD	CKD/diabetes	B, H	Payers, HCSAs, HCPs	[6]
		OCS-HeatMap	Severe asthma	B, H	Payers, HCSAs, HCPs	[7]
		ORBE II	Severe asthma	C, F, H	HCPs	[8-10]
		ORESTES	COPD	C, F, H	HCPs	[11]
		AZAHAR	SLE	C, F, H	HCPs	[12]
		COHERENT-HF	HF	B, H	HCPs, HCSAs	[13]
		COHERENT-COPD	COPD	H	HCPs, HCSAs	[14]
		CRIERFAC	CKD	G	Pharmacists, HCPs, HCSAs	[15]
	Health economics and outcomes research modeling	PROMETHEUS	COPD	B, E	Payers, HCSAs, HCPs	[16]
		INSIDE-CKD	CKD	B, E	Payers, HCSAs, HCPs	[17]

	Predictive analytics	DIABETIC@	CKD/diabetes	B	Payers, HCSAs, HCPs	[18]
		Predict 2 Prevent	CKD/diabetes	D, G	HCPs, HCSAs	[19]
		COMFE	HF	D, G	HCPs, HCSAs	[20]
	Patient-centered studies	LupusVoice	SLE	A, B	Payers, HCSAs, HCPs	[21]
		XALOC-1	Severe asthma	C, H	Payers, HCSAs, HCPs	[22]
Strategic use of evidence for the company	Generation of the Value Story	CARESA	Sustainability	B	HCSAs, HCPs	[23]
		CaReMe	CKD	B, D	HCSAs, HCPs	[24]
	Actionable data visualization and versatility	ATLAS	HF, CKD, asthma, COPD, HTN	B, H	HCSAs, HCPs	[25]
	Innovation and new technologies	PRECISEU	Precision medicine	G	HCPs, HCSAs	[26]
		UMBRELLA	Stroke	G	HCPs, HCSAs	[27]
		FAITHFUL	HF	G	HCPs, HCSAs	[28]

CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; HCPs: HealthCare Professionals; HCSAs: HealthCare System Administrators; HF: heart failure; HTN: hypertension; SLE: systemic lupus erythematosus. *List of strategic purposes or downstream applications: **(A)** P&R (Inclusion in product Value Dossier, for Price & Reimbursement negotiations); **(B)** Policy discussions (use of RWE data with payers and regulators to enable access to medicines at regional and local levels); **(C)** Differentiation from competitors; **(D)** Predictive models (identification of patients at higher risk of disease progression, non-responders, or those most likely to benefit from treatment); **(E)** Economic impact; **(F)** Inform guidelines; **(G)** Transforming Care (Support Healthcare Transformation activities); **(H)** Scientific narrative and ad-hoc materials to increase disease awareness and inform clinical decisions.

- [1] Sicras-Mainar A, Sicras-Navarro A, Palacios B, Varela L, Delgado JF. Epidemiology and treatment of heart failure in Spain: the HF-PATHWAYS study. *Rev Esp Cardiol (Engl Ed)*. 2022; 75(1):31-8. Epub 20201227. <http://dx.doi.org/10.1016/j.rec.2020.09.033>.
- [2] Nordon C, Rhodes K, Quint JK, Vogelmeier CF, Simons SO, Hawkins NM, et al. EXAcerbations of COPD and their OutcomeS on CardioVascular diseases (EXACOS-CV) Programme: protocol of multicountry observational cohort studies. *BMJ Open*. 2023; 13(4):e070022. Epub 20230426. <http://dx.doi.org/10.1136/bmjopen-2022-070022>.
- [3] Santos S, Manito N, Sánchez-Covisa J, Hernández I, Corregidor C, Escudero L, et al. Risk of severe cardiovascular events following COPD exacerbations: results from the EXACOS-CV study in Spain. *Rev Esp Cardiol (Engl Ed)*. 2025; 78(2):138-50. Epub 20240625. <http://dx.doi.org/10.1016/j.rec.2024.06.003>.
- [4] Alcázar-Navarrete B, Jamart L, Sánchez-Covisa J, Juárez M, Graefenhain R, Sicras-Mainar A. Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain. *Chest*. 2022; 162(5):1017-29. Epub 20220703. <http://dx.doi.org/10.1016/j.chest.2022.06.033>.
- [5] Sundström J, Bodegard J, Bollmann A, Vervloet MG, Mark PB, Karasik A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study. *Lancet Reg Health Eur*. 2022; 20:100438. Epub 20220630. <http://dx.doi.org/10.1016/j.lanepe.2022.100438>.
- [6] Martínez-Montoro JI, Aparicio-Sánchez JJ, Pimentel B, Juárez-Campo M, Alamillo ML, Fernández-García JC. Screening, prevalence, and burden of chronic kidney disease in people with type 2 diabetes managed by endocrinologists: A nationwide cross-sectional study. *Diabetes Res Clin Pract*. 2025; 112326. Epub 20250619. <http://dx.doi.org/10.1016/j.diabres.2025.112326>.
- [7] Almonacid C, Fitas E, Sánchez-Covisa J, Gutiérrez H, Rebollo P. Geographical differences in the use of oral corticosteroids in patients with severe asthma in Spain: heat map based on existing databases analyses. *BMC Pulm Med*. 2023; 23(1):3. Epub 20230104. <http://dx.doi.org/10.1186/s12890-022-02295-2>.
- [8] Padilla-Galo A, Moya Carmona I, Ausín P, Carazo Fernández L, García-Moguel I, Velasco-Garrido JL, et al. Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study. *Respir Res*. 2023; 24(1):235. Epub 20230928. <http://dx.doi.org/10.1186/s12931-023-02539-7>.
- [9] Ausín P, Navarrete-Rouco ME, Carazo L, Sanchez-Trincado JL, Luzon E, Nuevo J, et al. Early and Sustained Clinical Benefits of Benralizumab in Severe Eosinophilic Asthma: Findings from the ORBE II Study. *J Clin Med*. 2025; 14(9). Epub 20250426. <http://dx.doi.org/10.3390/jcm14093011>.
- [10] García-Moguel I, Martínez-Mesa Á, Andújar-Espinosa R, Díaz-Campos R, Velasco-Garrido JL, Sanchez-Trincado JL, et al. The impact of blood eosinophil count and FeNO on benralizumab effectiveness in clinical practice: An ORBE II subanalysis. *Respir Med*. 2025; 237:107940. Epub 20250113. <http://dx.doi.org/10.1016/j.rmed.2025.107940>.
- [11] Alcázar-Navarrete B, Figueira-Gonçalves JM, Corregidor-García C, Fitas E, Sánchez-Covisa J. Real-World Outcomes in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dehydrate in Spain: ORESTES Study. *Adv Ther*. 2025; 42(11):5708-26. Epub 20250922. <http://dx.doi.org/10.1007/s12325-025-03361-x>.
- [12] Galindo-Izquierdo M, Bahamontes-Rosa N, Sarto-Ferres B, Galvez-Fernandez M, Cortés-Hernández J. Characteristics and clinical outcomes of patients with systemic lupus erythematosus initiating anifrolumab in a real-world setting in Spain (AZAHAR study): an observational study protocol. *Lupus Sci Med*. 2025; 12(1). Epub 20250212. <http://dx.doi.org/10.1136/lupus-2024-001486>.
- [13] Bueno H, Goñi C, Salguero-Bodes R, Palacios B, Vicent L, Moreno G, et al. Primary vs. Secondary Heart Failure Diagnosis: Differences in Clinical Outcomes, Healthcare Resource Utilization and Cost. *Front Cardiovasc Med*. 2022; 9:818525. Epub 20220317. <http://dx.doi.org/10.3389/fcvm.2022.818525>.
- [14] Alvarez-Martinez CJ, Vélez J, Goñi C, Sánchez-Covisa J, Juárez-Campo M, Escudero L, et al. Application of the Clinical Outcomes, Healthcare Resource Utilization, and Related Costs Model in Chronic Obstructive Pulmonary Disease Patients. *Respiration*. 2025; 104(3):151-60.
- [15] Salar Ibáñez L, Espejo Guerrero J, Satué E, Pérez León N, Martínez-Berganza Asensio ML. [Screening for Chronic Kidney Disease in the Community Pharmacy. CRIERFAC Study: Description of the Methodology]. *Farm Comunitarios*. 2024; 16(2):5-13. Epub 20240411. [http://dx.doi.org/10.33620/fc.2173-9218.\(2024\).12](http://dx.doi.org/10.33620/fc.2173-9218.(2024).12).
- [16] Marín-Oto M, Mestre-Ferrándiz J, Sánchez-Covisa J, Corregidor García C, Martínez-Martínez N, Bell J, et al. Impact of increased single-inhaler triple therapy use in appropriate patients on COPD exacerbations, mortality, and medical costs: PROMETHEUS Spain. *Respiration*. 2025; 1-18. Epub 20251121. <http://dx.doi.org/10.1159/000549626>.
- [17] Navarro González JF, Ortiz A, Cebrián Cuenca A, Moreno Barón M, Segú L, Pimentel B, et al. Projection of the clinical and economic burden of chronic kidney disease between 2022 and 2027 in Spain: Results of the Inside CKD project. *Nefrología (Engl Ed)*. 2024; 44(6):807-17. Epub 20241203. <http://dx.doi.org/10.1016/j.nefro.2024.11.009>.
- [18] Blanco-Carrasco AJ, Merino-Torres JF, Rubio Almanza M, Canovas Molina G, Brito-Sanfiel MA, Barajas Galindo DE, et al. Characterizing the clinical profile and prevalence of people with diabetes attended in the hospital setting by using unstructured healthcare data and natural language processing: the Diabetic@ study. *Diabetes Res Clin Pract*. 2025; 112214. Epub 20250502. <http://dx.doi.org/10.1016/j.diabres.2025.112214>.
- [19] Navarro González JF, Perez de Isla L, Cánovas Molina G, Brito-Sanfiel MÁ, Barajas Galindo DE, Cuellar Olmedo LÁ, et al. Predicting CKD in Type 2 Diabetes Using Natural Language Processing on Healthcare Data. *Kidney Diseases*. 2025. <http://dx.doi.org/10.1159/000547604>.

- [20] Donoso-Trenado V, Otero-García Ó, López-Vilella R, de la Fuente López P, Martínez-Solé J, Yebra-Pimentel Brea C, et al. Factors Predicting Myocardial Recovery After Hospitalization for De Novo Heart Failure with Reduced Left Ventricular Ejection Fraction: Results from the COMFE Registry. *Biomedicines*. 2025; 13(5). Epub 20250508. <http://dx.doi.org/10.3390/biomedicines13051143>.
- [21] Galindo Izquierdo M, Borrás Blasco J, Pérez Ortega S, Salman-Monte TC, Vela-Casasempere P, Rodríguez Almaraz E, et al. Lack of awareness of systemic lupus erythematosus and its consequences in a cohort of moderate and severe patients in Spain: The LupusVoice study. *Lupus*. 2024; 33(7):663-74. Epub 20240405. <http://dx.doi.org/10.1177/09612033241242886>.
- [22] Jackson DJ, Pelaia G, Emmanuel B, Tran TN, Cohen D, Shih VH, et al. Benralizumab in severe eosinophilic asthma by biologic use and key clinical subgroups: real-world XALOC-1 programme: a plain language summary of publication. *Immunotherapy*. 2025; 17(2):71-81. Epub 20250211. <http://dx.doi.org/10.1080/1750743x.2025.2457931>.
- [23] AstraZeneca. CARESA – a pioneering tool to model the environmental impact of patient care pathways. [Internet] 2025; (accessed on 30 june 2025). Available from: <https://www.astrazeneca.com/media-centre/articles/2025/caresa-a-pioneering-tool-to-model-the-environmental-impact-of-patient-care-pathways.html>
- [24] Navarro-González JF, Ortiz A, Cebrián Cuenca A, Segú L, Pimentel B, Aranda U, et al. Evaluation of clinical events and costs associated with the addition of dapagliflozin to chronic kidney disease treatment: Cost offset analysis. *Nefrologia (Engl Ed)*. 2024; 44(6):857-67. Epub 20241206. <http://dx.doi.org/10.1016/j.nefro.2024.11.020>.
- [25] Medina J, Sánchez-Covisa J, Nuevo J, Palacios B, Roncero A, Alegría M, et al. Utilization of Evidence Blueprint Initiative to Transform Capability Development in AstraZeneca Spain. *Pharmaceut Med*. 2025. Epub 20250721. <http://dx.doi.org/10.1007/s40290-025-00575-w>.
- [26] PRECISEU. PeRsonalised medicine Empowerment Connecting Innovation ecoSystems across EUrope. [Internet] (accessed on 27 June 2025). Available from: <https://cordis.europa.eu/project/id/101161301>
- [27] UMBRELLA. Unleashing a comprehensive, holistic and patient centric stroke management for a better, rapid, advanced and personalised stroke diagnosis, treatment and outcome prediction. [Internet] (accessed on 27 June 2025). Available from: <https://www.ih.europa.eu/projects-results/project-factsheets/umbrella>
- [28] FAITHFUL. Future of Artificial intelligence trained for Heart Failure detection & Upgrading latest technology. EIT health 2023-SUD-3860 [Internet] 2023; (accessed on 27 June 2025). Available from: <https://eithealth.eu/product-service/faithful/>